Physician profile
Tamna Wangjam
NPI 1306134754
$1,368.53
in general payments reported to CMS, 2019-2025
21 companies · $26.42 in 2025
The $26.42 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.50 · 2020: $159 · 2021: $491 · 2022: $327 · 2023: $350 · 2025: $26.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $376.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $235.52 | 2020-2021 | |
| Kite Pharma, INC. | $170.01 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $163.06 | 2021-2023 | |
| Celgene Corporation | $102.48 | 2021-2023 | Pomalyst, Reblozyl |
| Adaptive Biotechnologies Corporation | $89.54 | 2023 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $84.94 | 2021-2023 | |
| Seagen INC. | $79.99 | 2022 | |
| Genentech USA, INC. | $58.25 | 2022-2023 | Venclexta |
| Eli Lilly and Company | $54.02 | 2023 | |
| Abbvie INC. | $53.15 | 2020-2025 | |
| Acrotech Biopharma INC. | $39.83 | 2022 | |
| Beigene USA, INC. | $35.75 | 2021-2023 | Brukinsa |
| Btg International INC. | $33.10 | 2019-2023 | |
| Janssen Biotech, INC. | $30.87 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $28.18 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $25.84 | 2023 | Vonjo |
| Karyopharm Therapeutics INC. | $20.83 | 2021 | |
| Gilead Sciences, INC. | $17.10 | 2022 | |
| Glaxosmithkline, LLC. | $16.77 | 2022 | |
| Janssen Scientific Affairs, LLC | $16.23 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamna Wangjam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.